Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARALLAX: LCZ696 in HFpEF
NCT03066804Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 32
01
Overview
A Phase 3 trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF), sponsored by Novartis. Started Aug 2017; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03066804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066804.